Fall 2025 Class Descriptions: Electives
Bankruptcy (LWBC510)
Instructor(s): Mary Jo Wiggins
3 credit(s), Letter Graded
Concentration(s): Business and Corporate Law (JD), LLM in Business and Corporate Law (LLMB), Business and Corporate Law (LLMUS), Business and Corporate Law (MSLS)
This course will provide an detailed examination of the liquidation and reorganization dynamics in both corporate and consumer cases under the Bankruptcy Code, and the effects of bankruptcy on non-bankruptcy debtor-creditor law, corporate workouts, and a variety of pre-bankruptcy transactions. The objective of this course is to give students a working knowledge of the Code and associated rules, cases and history; an understanding of the policies reflected in and relevant to bankruptcy law and non-bankruptcy debtor-creditor law; and an appreciation of the reality of modern bankruptcy practice. There are no course prerequisites. The course grade will be based on a traditional final exam and possibly a midterm.
Biotechnology Law (LWIP510)
Instructor(s): Stephen Ferruolo
2 credit(s), Letter Graded
Requirement(s): Writing
Concentration(s): Business and Corporate Law (JD), Intellectual Property (JD), LLM in Business and Corporate Law (LLMB), Business and Corporate Law (LLMUS), Intellectual Property (LLMUS), Intellectual Property Law (LLMG), Business and Corporate Law (MSLS), Intellectual Property Law (MSLS)
As one of the fastest growing industries in California (and throughout the world), biotechnology offers increasing opportunities for attorneys who can serve the broad and complex legal needs of companies developing biotech products. Developing these products, especially drugs and biologics, involves significant risks, long lead times, and typically many rounds and types of financing, including funding development through collaborations and strategic partnerships. Global intellectual property protection is also essential; biotech patents can be excessively expansive and must be pursued strategically. Biotech companies face many critical and complex regulatory hurdles to comply with a broad array of U.S. and international rules, obtain marketing approval, and satisfy governmental reimbursement and pricing requiremens. We will be reviewing these issues, risks and challenges topically, looking at case studies of notable biotech companies (including Genentech and Theranos) and inviting leading industry executives and legal practitioners to share their insights.
In addition to reading the assigned materials and participating in class discussion, each student will be required to write a substantial final paper on an approved topic related to biotechnology and the law. There will also be one or two shorter written assignments based on the readings.